A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder
CNS Drugs · 2024-12 · 38 (12) · 1003-1016
DOI: 10.1007/s40263-024-01124-w ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift CNS Drugs, online erschienen am 18.10.2024. Verfasst von Masaki Kato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Major Depressive Disorder, Thiophenes, Quinolones, Antidepressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Inadequate response to antidepressant monotherapy is common among patients with major depressive disorder (MDD). The efficacy and safety of adjunctive brexpiprazole 2 mg/day has recently been confirmed during the 6-week, randomized, placebo-controlled phase 2/3 (BLESS) study, which evaluated brexpiprazole at 1 mg/day and 2 mg/day versus placebo as adjunctive therapy to antidepressant therapies in 740 Japanese patients with MDD and an inadequate response to antidepressant monotherapy. This study evaluated the long-term safety and efficacy of adjunctive fixed-dose brexpiprazole 2 mg/day in Japanese patients with MDD. METHODS: An open-label, 52-week study enrolled rollover patients who completed the 6-week, double-blind, randomized, placebo-controlled phase 2/3 BLESS study (NCT03697603), and de novo patients aged ≥ 65 years. Patients were titrated to fixed-dose brexpiprazole 2 mg/day from Week 1. Safety assessments included treatment-emergent adverse events (TEAEs; primary outcome) and clinical and laboratory variables. Efficacy was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression-Improvement (CGI-I) scale, Hamilton Depression Rating Scale (HAM-D) 17-item total score, and Sheehan Disability Scale (SDS) score. RESULTS: In total, 247 patients [rollover, n = 216; de novo (previously unexposed), n = 31] were included in the safety/efficacy populations, and 138 (rollover, n = 132; de novo, n = 6; 55.9%) completed the study. Common TEAEs (incidence ≥ 10%) were weight gain [33.2% (n = 82)], akathisia [23.5% (n = 58)], nasopharyngitis [21.1% (n = 52)], and somnolence [10.5% (n = 26)]. TEAEs leading to treatment discontinuation occurred in 26.7% of patients receiving brexpiprazole and 58.1% of de novo patients. The mean (SD) increase in body weight from baseline to Week 52 [observed cases (OC)] was 4.2 (6.5) kg (n = 138); 44.5% (n = 110) had weight gain ≥ 7% at any postbaseline visit. There were no cases of tardive dyskinesia and no AEs related to suicide/suicide attempts. One death occurred (unknown cause), which was unrelated to study treatment. Improvements in the MADRS total score were observed from baseline over the course of the 52-week study [mean (SD) change at Week 52 (OC): - 7.3 (8.7)] for all patients receiving brexpiprazole. The overall MADRS response rate and remission rate in patients receiving brexpiprazole was 41.3% (n = 57) and 34.8% (n = 48), respectively, at Week 52 (OC). Improvements in CGI-S, HAM-D 17 item total score, and SDS mean scores were also observed from baseline over the 52-week study, with a mean (SD) change from baseline at Week 52 (OC) of - 0.8 (1.0), - 5.9 (6.3), and - 1.0 (2.2), respectively, indicating a sustained improvement in symptoms with long-term brexpiprazole treatment. CONCLUSIONS: This is the first study to evaluate the safety profile of brexpiprazole 2 mg/day in Japanese patients with MDD, including older adults, which is similar to previous reports, with no new safety risks, and continued efficacy over 52 weeks. STUDY REGISTRATION: ClinicalTrials.gov (NCT03737474; registered on 29 July 2018).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
- Clinical Development, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
- Clinical Development, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.
- Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower 2-16-4, Konan, Minato-ku, Tokyo, 108-8242, Japan.
- Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower 2-16-4, Konan, Minato-ku, Tokyo, 108-8242, Japan. aoki.kazuo@otsuka.jp.
- Japan Depression Center, Tokyo, Japan.
ORCID-Profile: Kazuo Aoki
Förderung
- Otsuka Pharmaceutical Co., Ltd.
Zitieren
APA
Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Sekine, D., Aoki, K., Shiomi, Y., & Higuchi, T. (2024). A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder. CNS Drugs, 38(12), 1003-1016. https://doi.org/10.1007/s40263-024-01124-w
Vancouver
Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, et al. A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder. CNS Drugs. 2024;38(12):1003-1016. doi:10.1007/s40263-024-01124-w
BibTeX
@article{Kato2024,
author = {Kato, Masaki and Shiosakai, Masako and Kuwahara, Kazuo and Iba, Katsuhiro and Shimada, Yuki and Saito, Mizuki and Sekine, Daisuke and Aoki, Kazuo and Shiomi, Yuki and Higuchi, Teruhiko},
title = {A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder},
journal = {CNS Drugs},
year = {2024},
volume = {38},
number = {12},
pages = {1003--1016},
doi = {10.1007/s40263-024-01124-w}
}
EUVIMED